Trial Profile
Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 01 Aug 2022 Results of an analysis assessed co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel published in the Breast Cancer Research and Treatment
- 01 May 2017 Status changed from active, no longer recruiting to completed.
- 24 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2021.